Trial Watch: BMS Opdivo & Yervoy Flunks Late-State Cancer Study

Nov 29, 2018 | Challenging Results, Oncology, Small Cell Lung Cancer

Lung Cancer Trial Failure

Douglas House of Seeking Alpha reports that Bristol-Myers Squibb (BMS) fell 3% after its announcement that a Phase 3 clinical trial—CheckMate-451, evaluating Opdivo (nivolumab) plus a low-dose Yervoy (ipilimumab) as maintenance therapy in patients with extensive-stage small cell lung cancer without disease progression after the completion of first-line chemo failed to achieve the primary endpoint of overall survival (OS) compared to placebo.


Pin It on Pinterest